Clinical Trial Results:
A phase II study to evaluate the safety, tolerability and efficacy of Cabozantinib in patients with hepatocellular carcinoma (HCC) and impaired liver function (Child-Pugh score B7-8) - CABOCHILD -
|
Summary
|
|
EudraCT number |
2019-001075-36 |
Trial protocol |
DE |
Global completion date |
|
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
|
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
11 Jul 2026
|
First version publication date |
11 Jul 2026
|
Other versions |
|
Summary report(s) |
Trial results 2019_001075_36 |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.